title: Oxytocin receptors and contractile response of the myometrium after long term infusion of prostaglandin F2 alpha, indomethacin, oxytocin and an oxytocin antagonist in rats.
abstract: Binding of [3H]oxytocin to isolated myometrial plasma membranes was not affected by the presence of prostaglandin (PG)F2 alpha or E2 in the incubation medium. Long-term treatment with PGF2 alpha or indomethacin had no effect on oxytocin receptor concentrations and dissociation constants of myometrial plasma membranes nor on maximal contractility or KM values of isolated uterine strips exposed to oxytocin. Infusion of oxytocin for 5 days in non-pregnant rats resulted in a decrease in oxytocin receptor concentrations in myometrial plasma membranes whereas the binding affinity to oxytocin was unaffected. Isolated uterine strips from similarly treated rats showed a reduced maximal contractile response to oxytocin and an elevated KM value, possibly indicating an influence of oxytocin on the coupling between receptor occupancy and contractility. Treatment for 5 days with desamino1-[D-Tyr(O-ethyl)2-Thr4-Orn8] oxytocin (an oxytocin antagonist) increased the concentration of myometrial oxytocin receptors. In addition KD values of these receptors were elevated. The present results indicate that prolonged exposure to oxytocin leads to a down-regulation of the myometrial receptor concentration, which is not caused by ligand-receptor interaction in itself. The concerted effect of oxytocin and prostaglandins on myometrial contraction does not appear to involve modulation of the oxytocin receptor by prostaglandins.
authors.affiliation: Department of Medical Physiology C, University of Copenhagen, Denmark.
authors.forename: T
authors.initials: T
authors.lastname: Engstrøm
authors.forename: A
authors.initials: A
authors.lastname: Atke
authors.forename: H
authors.initials: H
authors.lastname: Vilhardt
mesh_terms: D000818:Animals; D002462:Cell Membrane / Q000378:metabolism; D015237:Dinoprost; D004958:Estradiol / Q000494:pharmacology; D005260:Female; D066298:In Vitro Techniques; D007213:Indomethacin / Q000494:pharmacology*; D007700:Kinetics; D009215:Myometrium / Q000187:drug effects / Q000502:physiology*; D010121:Oxytocin / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000494:pharmacology*; D011460:Prostaglandins F / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D011945:Receptors, Angiotensin / Q000187:drug effects / Q000502:physiology*; D018045:Receptors, Oxytocin; D014590:Uterine Contraction / Q000187:drug effects*; D014668:Vasotocin / Q000031:analogs & derivatives / Q000494:pharmacology
chemical_list: D011460:Prostaglandins F; D011945:Receptors, Angiotensin; D018045:Receptors, Oxytocin; C047046:atosiban; D004958:Estradiol; D010121:Oxytocin; D015237:Dinoprost; D014668:Vasotocin; D007213:Indomethacin